We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Justice Department recovered $4.7 billion in False Claims Act settlements, with the largest recoveries coming from the life sciences industry at $1.2 billion in the last fiscal year. Read More
Gilead will have to pay Merck $2.5 billion for infringing a patent that covers the active ingredient of its blockbuster hepatitis C drugs, Salvadi and Harvoni, in the country’s largest ever judgment for an infringement. Read More
A majority of patent settlements reached last year in the European Union restricted the market entry of generics, according to a European Commission report. Read More
Drugmakers have expressed concern about the German government’s proposal to restrict drug pricing — contending that the measure penalizes research and development. Read More
After the FDA clamped down on its facilities most of the year, Lupin has received clearance from the agency to produce drugs again at its site in Goa, India. Read More
The U.S. government and life sciences industry groups have asked Japan not to change the country’s drug pricing system to annual price reviews and cuts, instead of the current two-year review. Read More
The FTC is urging a D.C. federal court not to postpone an order that requires Boehringer Ingelheim to hand over documents in a pay-for-delay lawsuit involving the blood thinner, Aggrenox. Read More